Journal of Inherited Metabolic Disease

, Volume 36, Issue 3, pp 535–542 | Cite as

A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene

  • Belén Pérez
  • Celia Medrano
  • Maria Jesus Ecay
  • Pedro Ruiz-Sala
  • Mercedes Martínez-Pardo
  • Magdalena Ugarte
  • Celia Pérez-Cerdá
Original Article

Abstract

Recent years have seen great advances in our knowledge of congenital disorders of glycosylation (CDG), a clinically and biochemically heterogeneous group of genetic diseases caused by defects in the synthesis (CDG-I) or processing (CDG-II) of glycans that form glycoconjugates. This paper reports a new subtype of non-neurological CDG involving the impaired cytoplasmic biosynthesis of nucleotide sugars needed for glycan biosynthesis. A patient presented with muscle fatigue, elevated creatine kinase, growth hormone deficiency, and first branchial arch syndrome. These findings, together with the abnormal type II plasma transferrin isoform profile detected, was compatible with a CDG. Functional testing and clinical analyses suggested a deficiency in the interconversion of glucose-1-phosphate and glucose-6-phosphate catalyzed by phosphoglucomutase (PGM1), a defect previously described as glycogenosis type XIV (GSDXIV, MIM 612934). PGM1 activity in patient-derived fibroblasts was significantly reduced, as was the quantity of immunoreactive PGM1 protein (Western blot assays). Mutation analysis of PGM1 and subsequent functional analysis investigating transient expression of PGM1 in immortalized patient fibroblasts, followed by ex vivo splicing assays using minigenes, allowed the characterization of two novel pathogenic mutations: c.871G>A (p.Gly291Arg) and c.1144 + 3A>T. The latter represents a severe splicing mutation leading to the out-of-frame skipping of exon 7 and the formation of a truncated protein (p.Arg343fs). MALDI mass spectra of permethylated protein N-glycans from the patient’s serum suggested a marked hypoglycosylation defect. The present findings confirm that, in addition to a rare muscular glycolytic defect, PGM1 deficiency causes a non-neurological disorder of glycosylation.

Notes

Acknowledgements

This work was funded by grants from the Spanish Ministerio de Ciencia e Innovación (PI10/00455 to BP and PI11/01254 to CPC). An institutional grant from the Fundación Ramón Areces to the Centro de Biología Molecular Severo Ochoa is gratefully acknowledged. Authors also thank Mª Teresa Alonso from Servicio Interdepartamental de Investigación (SIDI-UAM) for glycan analysis by MALDI-TOF-mass spectrometry.

Details of funding

The authors confirm independence from the sponsors, and the content of the article has not been influenced by the sponsors.

Conflict of interest

None.

Supplementary material

10545_2012_9525_MOESM1_ESM.docx (48 kb)
ESM 1(DOCX 47 kb)
10545_2012_9525_MOESM2_ESM.docx (15 kb)
ESM 2(DOCX 15 kb)

References

  1. Azakir BA, Di Fulvio S, Kinter J, Sinnreich M (2012) Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J Biol Chem 287:10344–10354PubMedCrossRefGoogle Scholar
  2. Bang YL, Nguyen TT, Trinh TT, Kim YJ, Song J, Song YH (2009) Functional analysis of mutations in UDP-galactose-4-epimerase (GALE) associated with galactosemia in Korean patients using mammalian GALE-null cells. FEBS J 276:1952–1961PubMedCrossRefGoogle Scholar
  3. Freeze HH, Sharma V (2010) Metabolic manipulation of glycosylation disorders in humans and animal models. Semin Cell Dev Biol 21:655–662PubMedCrossRefGoogle Scholar
  4. Guillard M, Morava E, van Delft FL, Hague R, Korner C, Adamowicz M, Wevers RA, Lefeber DJ (2011) Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin Chem 57:593–602PubMedCrossRefGoogle Scholar
  5. Jaeken J (2010) Congenital disorders of glycosylation. Ann N Y Acad Sci 1214:190–198PubMedCrossRefGoogle Scholar
  6. Lai K, Langley SD, Khwaja FW, Schmitt EW, Elsas LJ (2003) GALT deficiency causes UDP-hexose deficit in human galactosemic cells. Glycobiology 13:285–294PubMedCrossRefGoogle Scholar
  7. Lefeber DJ, Morava E, Jaeken J (2011) How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis 34:849–852PubMedCrossRefGoogle Scholar
  8. Mills PB, Mills K, Mian N, Winchester BG, Clayton PT (2003) Mass spectrometric analysis of glycans in elucidating the pathogenesis of CDG type IIx. J Inherit Metab Dis 26:119–134PubMedCrossRefGoogle Scholar
  9. Morava E, Lefeber D (2011) CDG - an update. J Inherit Metab Dis 34:847–848PubMedCrossRefGoogle Scholar
  10. Morelle W, Michalski JC (2007) Analysis of protein glycosylation by mass spectrometry. Nat Protoc 2:1585–1602PubMedCrossRefGoogle Scholar
  11. Perez-Cerda C, Clavero S, Perez B, Rodriguez-Pombo P, Desviat LR, Ugarte M (2003) Functional analysis of PCCB mutations causing propionic acidemia based on expression studies in deficient human skin fibroblasts. Biochim Biophys Acta 1638:43–49PubMedCrossRefGoogle Scholar
  12. Perez-Cerda C, Quelhas D, Vega AI, Ecay J, Vilarinho L, Ugarte M (2008) Screening using serum percentage of carbohydrate-deficient transferrin for congenital disorders of glycosylation in children with suspected metabolic disease. Clin Chem 54:93–100PubMedCrossRefGoogle Scholar
  13. Putt W, Ives JH, Hollyoake M, Hopkinson DA, Whitehouse DB, Edwards YH (1993) Phosphoglucomutase 1: a gene with two promoters and a duplicated first exon. Biochem J 296(Pt 2):417–422PubMedGoogle Scholar
  14. Rincon A, Aguado C, Desviat LR, Sanchez-Alcudia R, Ugarte M, Perez B (2007) Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet 81:1262–1270PubMedCrossRefGoogle Scholar
  15. Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen MC, Andersen G, Claeys KG, Wary C, Hogrel JY, Laforet P (2009) Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 361:425–427PubMedCrossRefGoogle Scholar
  16. Sturiale L, Barone R, Fiumara A, Perez M, Zaffanello M, Sorge G, Pavone L, Tortorelli S, O’Brien JF, Jaeken J, Garozzo D (2005) Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology 15:1268–1276PubMedCrossRefGoogle Scholar
  17. Van Schaftingen E, Jaeken J (1995) Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett 377:318–320PubMedCrossRefGoogle Scholar
  18. Wopereis S, Grunewald S, Morava E, Penzien JM, Briones P, Garcia-Silva MT, Demacker PN, Huijben KM, Wevers RA (2003) Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis. Clin Chem 49:1839–1845PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  • Belén Pérez
    • 1
  • Celia Medrano
    • 1
  • Maria Jesus Ecay
    • 1
  • Pedro Ruiz-Sala
    • 1
  • Mercedes Martínez-Pardo
    • 2
  • Magdalena Ugarte
    • 1
  • Celia Pérez-Cerdá
    • 1
    • 3
  1. 1.Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular UAM-CSIC, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)IDIPaz, Universidad Autónoma MadridMadridSpain
  2. 2.Unidad de Metabolopatías, Servicio de Pediatría, Hospital Ramón y CajalMadridSpain
  3. 3.Centro de Diagnóstico de Enfermedades MolecularesUniversidad Autónoma MadridMadridSpain

Personalised recommendations